Nu Holdings (NU) Is Down 8.8% After Announcing First-Ever $1B Buyback And CFO Transition

Nu Holdings

Nu Holdings

NU

0.00

  • Nu Holdings Ltd. recently announced its first-ever share repurchase program, authorizing up to US$1.00 billion in buybacks over 12 months funded by retained and future earnings, alongside a planned CFO transition from Guilherme Lago to Rob Livingston in July 2026.
  • This combination of a sizeable buyback and the arrival of a veteran finance leader from Visa puts fresh attention on Nu’s capital allocation and leadership depth as it expands across Latin America and the United States.
  • Now, we’ll examine how the newly announced US$1.00 billion buyback could reshape Nu Holdings’ investment narrative and long-term thesis.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Nu Holdings Investment Narrative Recap

To own Nu Holdings, you need to believe app-based banking can keep gaining share as Latin America and the US shift from cash to digital, and that Nu can manage credit risk as it moves deeper into mass-market lending. The US$1.00 billion buyback and CFO transition draw attention to capital discipline and leadership stability, but they do not fundamentally change the near-term catalyst of product and geographic expansion, or the key risk around credit quality in less mature borrower segments.

Among the recent announcements, the OCC’s conditional approval for a new US national bank (Nubank, N.A.) is especially relevant. It directly links to Nu’s core growth catalyst of multi-country expansion, potentially broadening its deposit and lending base while also increasing regulatory and operational complexity. How Nu balances this higher compliance burden with its push into underbanked US segments will matter at least as much as the new buyback in shaping future outcomes.

Yet beneath the excitement around buybacks and new markets, investors also need to be aware of the growing exposure to riskier borrowers and...

Nu Holdings’ narrative projects $33.0 billion revenue and $6.1 billion earnings by 2028. This requires 78.1% yearly revenue growth and about a $3.8 billion earnings increase from $2.3 billion today.

Uncover how Nu Holdings' forecasts yield a $19.99 fair value, a 67% upside to its current price.

Exploring Other Perspectives

NU 1-Year Stock Price Chart
NU 1-Year Stock Price Chart

Compared with consensus, the most cautious analysts were already assuming revenue of about US$34.4 billion and earnings near US$6.3 billion by 2029, yet still worry that expanding into riskier, underserved markets could raise long run credit losses and compress margins, so this new buyback and CFO change may prompt you to revisit which version of Nu’s future feels more realistic.

Explore 20 other fair value estimates on Nu Holdings - why the stock might be worth over 5x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Nu Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
  • Our free Nu Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nu Holdings' overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

  • The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
  • The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
  • AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.